Clinical Trial

Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)

Study acronym: NeoTempo
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to explore the optimal course of neoadjuvant immunotherapy for HNSCC by comparing the efficacy and safety of 4 cycles and 2 cycles of neoadjuvant tislelizumab combined with chemotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-28.
Status change: Not Yet Recruiting → Recruiting 2026-07-21
Trial Details
NCT Number NCT07147426
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions Head & Neck Squamous Cell Carcinoma
Enrollment 100 participants
Start Date 2025-10-01
Primary Completion 2027-10-20 (estimated)
Study Completion 2029-10-20 (estimated)
Updated on ClinicalTrials.gov 2026-07-22